Janux Therapeutics Inc
JANX14.250USD
-0.060-0.42%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
856.76MMarket Cap
LossP/E TTM
More Details of Janux Therapeutics Inc Company
Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. It has developed two bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. Its clinical candidates include JANX007 and JANX008. JANX007 is a prostate-specific membrane antigen (PSMA-TRACTr) designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors. JANX008 is an epidermal growth factor receptor (EGFR-TRACTr), being studied for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Janux Therapeutics Inc Info
Ticker SymbolJANX
Company nameJanux Therapeutics Inc
IPO dateJun 11, 2021
CEOCampbell (David)
Number of employees74
Security typeOrdinary Share
Fiscal year-endJun 11
Address10955 Vista Sorrento Parkway
CitySAN DIEGO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92130
Phone18587514493
Websitehttps://www.januxrx.com/
Ticker SymbolJANX
IPO dateJun 11, 2021
CEOCampbell (David)
Company Executives of Janux Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Independent Director
Independent Director
116.39K
+3.33%
Mr. Charles Winter
Mr. Charles Winter
Chief Technical Officer
Chief Technical Officer
74.46K
+44.70%
Ms. Janeen Doyle
Ms. Janeen Doyle
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
44.00K
--
Ms. Natasha A. Hernday
Ms. Natasha A. Hernday
Independent Director
Independent Director
3.75K
--
Dr. Ronald W. (Ron) Barrett, Ph.D.
Dr. Ronald W. (Ron) Barrett, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
3.75K
--
Mr. Eric L. Dobmeier, J.D.
Mr. Eric L. Dobmeier, J.D.
Independent Director
Independent Director
3.75K
--
Dr. Jake Simson, Ph.D.
Dr. Jake Simson, Ph.D.
Independent Director
Independent Director
3.75K
--
Dr. Thomas Diraimondo, Ph.D.
Dr. Thomas Diraimondo, Ph.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
--
--
Dr. David Campbell, Ph.D.
Dr. David Campbell, Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
--
--
Ms. Alana B. Mcnulty
Ms. Alana B. Mcnulty
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Sheila Gujrathi, M.D.
Dr. Sheila Gujrathi, M.D.
Independent Director
Independent Director
116.39K
+3.33%
Mr. Charles Winter
Mr. Charles Winter
Chief Technical Officer
Chief Technical Officer
74.46K
+44.70%
Ms. Janeen Doyle
Ms. Janeen Doyle
Chief Corporate and Business Development Officer
Chief Corporate and Business Development Officer
44.00K
--
Ms. Natasha A. Hernday
Ms. Natasha A. Hernday
Independent Director
Independent Director
3.75K
--
Dr. Ronald W. (Ron) Barrett, Ph.D.
Dr. Ronald W. (Ron) Barrett, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
3.75K
--
Mr. Eric L. Dobmeier, J.D.
Mr. Eric L. Dobmeier, J.D.
Independent Director
Independent Director
3.75K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
RA Capital Management, LP
18.60%
Fidelity Management & Research Company LLC
14.04%
Janus Henderson Investors
7.82%
BlackRock Institutional Trust Company, N.A.
5.34%
Bregua Corp
4.99%
Other
49.20%
Shareholders
Shareholders
Proportion
RA Capital Management, LP
18.60%
Fidelity Management & Research Company LLC
14.04%
Janus Henderson Investors
7.82%
BlackRock Institutional Trust Company, N.A.
5.34%
Bregua Corp
4.99%
Other
49.20%
Shareholder Types
Shareholders
Proportion
Investment Advisor
33.94%
Hedge Fund
24.55%
Investment Advisor/Hedge Fund
23.45%
Venture Capital
20.25%
Corporation
4.99%
Private Equity
3.42%
Research Firm
2.83%
Individual Investor
1.73%
Pension Fund
0.80%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
405
67.14M
111.63%
-9.60M
2025Q2
406
71.98M
121.61%
-4.34M
2025Q1
413
73.50M
124.27%
-3.92M
2024Q4
403
71.29M
120.67%
+11.65M
2024Q3
335
56.66M
107.54%
-2.86M
2024Q2
298
57.26M
111.36%
+52.19K
2024Q1
242
56.34M
109.98%
+6.39M
2023Q4
179
48.33M
104.72%
-1.60M
2023Q3
169
48.51M
108.17%
+3.13M
2023Q2
166
43.90M
105.07%
-4.39M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
11.19M
18.62%
--
--
Jun 30, 2025
Fidelity Management & Research Company LLC
8.63M
14.36%
+35.87K
+0.42%
Jun 30, 2025
Janus Henderson Investors
4.46M
7.42%
-137.76K
-3.00%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.92M
4.85%
+400.99K
+15.94%
Jun 30, 2025
Bregua Corp
3.00M
4.99%
-830.27K
-21.68%
Sep 30, 2024
Paradigm BioCapital Advisors LP
2.92M
4.86%
-409.65K
-12.30%
Jun 30, 2025
Adage Capital Management, L.P.
2.52M
4.2%
-1.13M
-30.91%
Jun 30, 2025
The Vanguard Group, Inc.
2.18M
3.63%
-89.23K
-3.93%
Jun 30, 2025
State Street Investment Management (US)
1.39M
2.31%
+16.61K
+1.21%
Jun 30, 2025
OrbiMed Advisors, LLC
1.21M
2.01%
+451.73K
+59.55%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
3.02%
Tema Oncology ETF
1.82%
Virtus LifeSci Biotech Clinical Trials ETF
0.76%
State Street SPDR S&P Biotech ETF
0.53%
Direxion Daily S&P Biotech Bull 3X Shares
0.33%
ProShares Ultra Nasdaq Biotechnology
0.25%
Invesco Nasdaq Biotechnology ETF
0.17%
iShares Biotechnology ETF
0.14%
T Rowe Price Small-Mid Cap ETF
0.09%
Pacer WealthShield ETF
0.08%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion3.02%
Tema Oncology ETF
Proportion1.82%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.76%
State Street SPDR S&P Biotech ETF
Proportion0.53%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.33%
ProShares Ultra Nasdaq Biotechnology
Proportion0.25%
Invesco Nasdaq Biotechnology ETF
Proportion0.17%
iShares Biotechnology ETF
Proportion0.14%
T Rowe Price Small-Mid Cap ETF
Proportion0.09%
Pacer WealthShield ETF
Proportion0.08%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Janux Therapeutics Inc?
The top five shareholders of Janux Therapeutics Inc are:
RA Capital Management, LP holds 11.19M shares, accounting for 18.62% of the total shares.
Fidelity Management & Research Company LLC holds 8.63M shares, accounting for 14.36% of the total shares.
Janus Henderson Investors holds 4.46M shares, accounting for 7.42% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.92M shares, accounting for 4.85% of the total shares.
Bregua Corp holds 3.00M shares, accounting for 4.99% of the total shares.
RA Capital Management, LP holds 11.19M shares, accounting for 18.62% of the total shares.
Fidelity Management & Research Company LLC holds 8.63M shares, accounting for 14.36% of the total shares.
Janus Henderson Investors holds 4.46M shares, accounting for 7.42% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 2.92M shares, accounting for 4.85% of the total shares.
Bregua Corp holds 3.00M shares, accounting for 4.99% of the total shares.
What are the top three shareholder types of Janux Therapeutics Inc?
The top three shareholder types of Janux Therapeutics Inc are:
RA Capital Management, LP
Fidelity Management & Research Company LLC
Janus Henderson Investors
RA Capital Management, LP
Fidelity Management & Research Company LLC
Janus Henderson Investors
How many institutions hold shares of Janux Therapeutics Inc (JANX)?
As of 2025Q3, 405 institutions hold shares of Janux Therapeutics Inc, with a combined market value of approximately 67.14M, accounting for 111.63% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -9.99%.
What is the biggest source of revenue for Janux Therapeutics Inc?
In --, the -- business generated the highest revenue for Janux Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
